# ALZN (Alzamend Neuro, Inc.) - SEC EDGAR Financial Statements

> Alzamend Neuro, Inc. reported $8.54M in total assets and a net loss of $9.10M through April 30, 2026 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ALZN
- Markdown: https://convexityos.com/fundamentals/ALZN.md
- SEC CIK: 0001677077
- Reporting currency: USD
- Latest filing period: July 31, 2026
- Last synced: Nov 21, 2026, 05:08 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001677077&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2026 | -- | Apr 30, 2026 |
| Operating Income | FY 2026 | -$9.09M | Operating profit |
| Net Income | FY 2026 | -$9.10M | GAAP bottom line |
| Diluted EPS | FY 2026 | -$2.03 | Split-adjusted |
| Free Cash Flow | FY 2026 | -- | Operating CF less CapEx |
| Cash & ST Investments | Jul 31, 2026 | $7.59M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $3.63M | $1.41M | $6.46M | $7.45M | $5.20M | $1.31M | $1.07M |
| Total Operating Expenses | $8.77M | $4.50M | $9.94M | $14.87M | -- | -- | -- |
| **Operating Income** | -$8.77M | -$4.50M | -$9.94M | -$14.87M | -$12.32M | -$4.95M | -$4.42M |
| **EBITDA** | -$8.66M | -$4.45M | -$9.89M | -$14.85M | -$12.32M | -- | -- |
| Interest Income | $1.1K | -- | -- | -- | -- | -- | -- |
| Interest Expense | $6.6K | $18K | $10K | $7.7K | $47K | $142K | -- |
| Income Before Tax | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M |
| **Net Income** | -$8.77M | -$4.51M | -$9.95M | -$14.88M | -$12.36M | -$5.05M | -$4.41M |
| Basic EPS | -$2.63 | -$11.32 | -$132.33 | -$2,088.50 | -$1,906.53 | -$953.26 | -$817.08 |
| **Diluted EPS** | -$2.63 | -$11.32 | -$132.33 | -$2,088.50 | -$1,906.53 | -$953.26 | -$817.08 |
| Basic Shares Outstanding | 3.3M | 450.8K | 74.2K | 7.1K | 6.5K | 5.3K | 5.2K |
| Diluted Shares Outstanding | 3.3M | 450.8K | 74.2K | 7.1K | 6.5K | 5.3K | 5.2K |

### Income Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.09M | $434K | $1.28M | $176K | $1.74M | $450K | $447K | $311K |
| Total Operating Expenses | $3.03M | $2.87M | $2.20M | $998K | $2.70M | $1.14M | $1.04M | $1.36M |
| **Operating Income** | -$3.03M | -$2.87M | -$2.20M | -$998K | -$2.70M | -$1.14M | -$1.04M | -$1.36M |
| **EBITDA** | -$3.00M | -$2.84M | -$2.17M | -$970K | -$2.67M | -$1.13M | -$1.02M | -$1.35M |
| Interest Income | $399 | -- | -- | -- | -- | -- | -- | -- |
| Interest Expense | $2.0K | $150 | $1.3K | $2.6K | $2.5K | $509 | $2.0K | $3.5K |
| **Net Income** | -$3.03M | -$2.87M | -$2.20M | -$1.00M | -$2.70M | -$1.14M | -$1.04M | -$1.36M |
| Basic EPS | -$0.68 | -- | -$0.58 | -$0.30 | -$1.28 | -- | -$1.75 | -$3.61 |
| **Diluted EPS** | -$0.68 | -- | -$0.58 | -$0.30 | -$1.28 | -- | -$1.75 | -$3.61 |
| Basic Shares Outstanding | 4.5M | -- | 3.8M | 3.4M | 2.1M | -- | 612.0K | 392.4K |
| Diluted Shares Outstanding | 4.5M | -- | 3.8M | 3.4M | 2.1M | -- | 612.0K | 392.4K |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $711K | $3.95M | $376K | $5.14M | $14.06M | $1.93M | $90K |
| **Cash & Short-Term Investments** | $711K | $3.95M | $376K | $5.14M | $14.06M | $1.93M | $90K |
| **Total Current Assets** | $1.76M | $4.18M | $455K | $5.84M | $14.41M | $2.91M | $1.81M |
| Property, Plant & Equipment, Net | $315K | $426K | $176K | $80K | $103K | -- | -- |
| **Total Non-Current Assets** | $315K | $426K | $176K | $80K | $103K | $0 | $0 |
| **Total Assets** | $2.08M | $4.60M | $632K | $5.92M | $14.52M | $2.91M | $1.81M |
| Accounts Payable | -- | -- | $2.93M | $2.87M | $1.16M | $504K | $930K |
| **Total Current Liabilities** | -- | -- | -- | $2.87M | $1.16M | $900K | $992K |
| **Total Non-Current Liabilities** | -- | -- | -- | $0 | $0 | $0 | $0 |
| **Total Liabilities** | $1.35M | $635K | $3.23M | $2.87M | $1.16M | $900K | $992K |
| Common Stock | $425 | $78 | $8 | $65 | $9.5K | $6.7K | $6.5K |
| Retained Earnings | -$67.31M | -$58.54M | -$54.02M | -$44.07M | -$29.19M | -$16.83M | -$11.79M |
| **Total Stockholders' Equity** | $733K | $3.97M | -$2.59M | $3.05M | $13.35M | $2.01M | $822K |
| Total Equity | $733K | $3.97M | -$2.59M | $3.05M | $13.35M | $2.01M | $822K |

### Balance Sheet (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $7.59M | $711K | $2.71M | $4.45M | $5.62M | $3.95M | $3.36M | $4.09M |
| **Cash & Short-Term Investments** | $7.59M | $711K | $2.71M | $4.45M | $5.62M | $3.95M | $3.36M | $4.09M |
| **Total Current Assets** | $8.25M | $1.76M | $3.70M | $4.72M | $5.93M | $4.18M | $3.95M | $4.77M |
| Property, Plant & Equipment, Net | $287K | $315K | $343K | $370K | $398K | $426K | $228K | $241K |
| **Total Non-Current Assets** | $287K | $315K | $343K | $370K | $398K | $426K | $228K | $241K |
| **Total Assets** | $8.54M | $2.08M | $4.04M | $5.09M | $6.33M | $4.60M | $4.18M | $5.01M |
| Accounts Payable | -- | -- | -- | -- | -- | -- | $726K | $1.25M |
| **Total Liabilities** | $2.74M | $1.35M | $1.86M | $717K | $983K | $635K | $726K | $1.25M |
| Common Stock | $482 | $425 | $380 | $380 | $314 | $78 | $580 | $523 |
| Retained Earnings | -$70.33M | -$67.31M | -$64.44M | -$62.24M | -$61.24M | -$58.54M | -$57.40M | -$56.41M |
| **Total Stockholders' Equity** | $5.80M | $733K | $2.20M | $4.37M | $5.34M | $3.97M | $3.45M | $3.75M |
| Total Equity | $5.80M | $733K | $2.20M | $4.37M | $5.34M | $3.97M | $3.45M | $3.75M |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | $8.80M | $4.50M | $9.90M | $14.90M | -$12.36M | -$5.05M | -$4.41M |
| Depreciation & Amortization | $111K | $51K | $51K | $23K | $3.5K | -- | -- |
| Stock-Based Compensation | $708K | $325K | $956K | $3.58M | $4.41M | $2.03M | $1.80M |
| Change in Payables | -- | -- | -- | $1.71M | $694K | -$413K | -$175K |
| **Operating Cash Flow** | -$8.07M | -$6.57M | -$8.27M | -$8.92M | -$6.61M | -$2.71M | -$2.35M |
| **Investing Cash Flow** | -- | -$300K | -$147K | -- | -$106K | $101K | $105K |
| Common Stock Issued | $795K | $2.70M | $1.25M | -- | $6.00M | $2.10M | $2.29M |
| **Financing Cash Flow** | $4.83M | $10.44M | $3.65M | $200 | $18.85M | $4.45M | $2.29M |
| **Net Change in Cash** | -$3.24M | $3.57M | -$4.76M | -$8.92M | $12.13M | -- | -- |

### Cash Flow Statement (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.03M | $14.70M | -$2.20M | -$1.00M | -$2.70M | $7.88M | -$1.04M | -$1.36M |
| Depreciation & Amortization | $28K | $28K | $28K | $28K | $28K | $13K | $13K | $13K |
| Stock-Based Compensation | $77K | $624K | $9.3K | $32K | $43K | $81K | $81K | $81K |
| **Operating Cash Flow** | -$1.14M | -$2.80M | -$1.74M | -$1.17M | -$2.36M | -$689K | -$1.42M | -$3.40M |
| **Investing Cash Flow** | -- | -- | -- | -- | -- | -$210K | $0 | $0 |
| Common Stock Issued | $669K | -- | -- | -- | -- | -- | -- | -- |
| **Financing Cash Flow** | $8.02M | $795K | $0 | $0 | $4.04M | $1.49M | $689K | $6.30M |
| **Net Change in Cash** | $6.88M | -$2.00M | -$1.74M | -$1.17M | $1.67M | $591K | -$735K | $2.90M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -1196.4% | -113.8% | -- | -488.5% | -92.6% | -250.7% | -536.7% |
| Return on Assets (ROA) | -421.9% | -98.1% | -1575.0% | -251.5% | -85.2% | -173.3% | -243.1% |
| Current Ratio | -- | -- | -- | 2.03x | 12.37x | 3.24x | 1.83x |
| Quick Ratio | -- | -- | -- | 1.79x | 12.07x | 2.14x | 0.09x |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Jul 2026 | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -156.8% | -1196.4% | -320.1% | -134.5% | -116.8% | -113.8% | -122.5% | -155.9% |
| Return on Assets (ROA) | -106.5% | -421.9% | -174.2% | -115.5% | -98.7% | -98.1% | -101.2% | -116.8% |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
